Anatara Lifesciences Ltd (ASX:ANR)
0.0110
0.00 (0.00%)
Mar 3, 2026, 2:03 PM AEST
Anatara Lifesciences Revenue
Anatara Lifesciences had revenue of 446.20K AUD in the half year ending June 30, 2025. This brings the company's revenue in the last twelve months to 623.76K, down -30.27% year-over-year. In the fiscal year ending June 30, 2025, Anatara Lifesciences had annual revenue of 969.46K with 50.53% growth.
Revenue (ttm)
623.76K
Revenue Growth
-30.27%
P/S Ratio
5.57
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 969.46K | 325.43K | 50.53% |
| Jun 30, 2024 | 644.03K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 9.75M |
| Immuron | 7.48M |
| Tissue Repair | 3.26M |
| Acrux | 2.81M |
| Nexalis Therapeutics | 767.69K |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |
| Invex Therapeutics | 229.08K |